New drug combo for HR-positive breast cancer with brain spread
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug combination (culmerciclib, anlotinib, and hormone therapy) for people with HR-positive, HER2-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink brain tumors and control the cancer for as long as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You have HR-positive, HER2-negative breast cancer that has spread to the brain, with at least one measurable brain tumor
- Your brain metastases are not urgent (no need for immediate radiation or surgery)
- You have not had more than 3 prior treatments for advanced disease, and no more than one line of chemotherapy or antibody-drug conjugate
- If you have taken a CDK4/6 inhibitor before, it must have been only one line and for more than 6 months
- You have not had prior treatment with anti-angiogenic drugs (like bevacizumab) or the experimental drug culmerciclib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Culmerciclib for women with a certain type of advanced breast cancer that has both hormone receptors and HER2. It’s for patients whose cancer has been stable on at least 4 cycles of prior therapy.
This trial tests a new drug called culmerciclib when given with hormone therapy before breast cancer surgery. The goal is to see if this combination can shrink tumors and improve outcomes for patients with hormone-receptor-positive, HER2-negative breast cancer.
This trial tests a combination of radiation to the brain, a hormone therapy, and a targeted drug called dalpiciclib for people with advanced breast cancer that has spread to the brain. The goal is to see if this combination can help control the cancer in the brain and elsewhere.
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
Hear when a new HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.